StockNews.com Lowers IQVIA (NYSE:IQV) to Hold

IQVIA (NYSE:IQV) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

IQV has been the subject of a number of other research reports. Royal Bank of Canada assumed coverage on shares of IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective for the company. JPMorgan Chase & Co. upped their price target on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Morgan Stanley upped their price target on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Finally, Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Stock Up 0.0 %

Shares of NYSE IQV opened at $228.31 on Tuesday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a market capitalization of $41.62 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.26 and a beta of 1.49. The stock has a 50 day moving average price of $238.71 and a 200 day moving average price of $230.92. IQVIA has a 52-week low of $167.42 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.22 earnings per share. Sell-side analysts expect that IQVIA will post 10.25 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently modified their holdings of the company. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the 2nd quarter worth about $27,000. Park Place Capital Corp purchased a new stake in shares of IQVIA during the 3rd quarter worth about $28,000. Itau Unibanco Holding S.A. purchased a new stake in shares of IQVIA during the 2nd quarter worth about $29,000. Finally, Riverview Trust Co purchased a new stake in shares of IQVIA during the 1st quarter worth about $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.